Form 4 for AVIR Atea Pharmaceuticals, Inc.
Accepted 2026-03-13 00:00:00 ET · period of report 2026-03-11 · accession 0001193125-26-106547 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-13 | 2026-03-11 | AVIR | Corcoran Andrea | See Remarks | M - OptEx | $1.24 | +60.0K | 823.6K | +8% | +$74.4K |
| D | 2026-03-13 | 2026-03-11 | AVIR | Corcoran Andrea | See Remarks | M - OptEx | $0.00 | +60.0K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-11 | M | A | 60,000 | $1.24 | 823,576 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-03-11 | M | A | 60,000 | $0.00 | 0 | D | $1.24 · — to 2026-12-08 | 60,000 Common Stock | (F1) The option is fully vested and exercisable. |